CL2011001769A1 - Composición para estimular una respuesta inmune contra la toxina shiga stx2 que comprende polipéptidos que comprenden al menos dos de las tres regiones que definen un epitopo conformacional exclusivo de stx2, los cuales se insertan dentro de una proteína andamio no stx2; dicho polipéptido; ácido nucleico; y método de producción de anticuerpos. - Google Patents
Composición para estimular una respuesta inmune contra la toxina shiga stx2 que comprende polipéptidos que comprenden al menos dos de las tres regiones que definen un epitopo conformacional exclusivo de stx2, los cuales se insertan dentro de una proteína andamio no stx2; dicho polipéptido; ácido nucleico; y método de producción de anticuerpos.Info
- Publication number
- CL2011001769A1 CL2011001769A1 CL2011001769A CL2011001769A CL2011001769A1 CL 2011001769 A1 CL2011001769 A1 CL 2011001769A1 CL 2011001769 A CL2011001769 A CL 2011001769A CL 2011001769 A CL2011001769 A CL 2011001769A CL 2011001769 A1 CL2011001769 A1 CL 2011001769A1
- Authority
- CL
- Chile
- Prior art keywords
- stx2
- polypeptides
- stimulating
- polypeptide
- define
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 title abstract 2
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 title abstract 2
- 101710204410 Scaffold protein Proteins 0.000 title abstract 2
- 230000028993 immune response Effects 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 230000004936 stimulating effect Effects 0.000 title abstract 2
- 239000003053 toxin Substances 0.000 title abstract 2
- 231100000765 toxin Toxicity 0.000 title abstract 2
- 230000016784 immunoglobulin production Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 108010090763 Shiga Toxin 2 Proteins 0.000 abstract 3
- 102100035936 Syntaxin-2 Human genes 0.000 abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14689209P | 2009-01-23 | 2009-01-23 | |
| US21008209P | 2009-03-13 | 2009-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011001769A1 true CL2011001769A1 (es) | 2012-08-31 |
Family
ID=42356196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011001769A CL2011001769A1 (es) | 2009-01-23 | 2011-07-21 | Composición para estimular una respuesta inmune contra la toxina shiga stx2 que comprende polipéptidos que comprenden al menos dos de las tres regiones que definen un epitopo conformacional exclusivo de stx2, los cuales se insertan dentro de una proteína andamio no stx2; dicho polipéptido; ácido nucleico; y método de producción de anticuerpos. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8969529B2 (enExample) |
| EP (1) | EP2381954B8 (enExample) |
| JP (1) | JP5773886B2 (enExample) |
| KR (1) | KR101832499B1 (enExample) |
| CN (1) | CN102292098A (enExample) |
| AR (1) | AR075047A1 (enExample) |
| AU (1) | AU2010206800B2 (enExample) |
| BR (1) | BRPI1007230B1 (enExample) |
| CA (1) | CA2748873C (enExample) |
| CL (1) | CL2011001769A1 (enExample) |
| ES (1) | ES2614803T3 (enExample) |
| MX (1) | MX2011007866A (enExample) |
| NZ (1) | NZ593926A (enExample) |
| PE (1) | PE20120425A1 (enExample) |
| RU (1) | RU2011126896A (enExample) |
| WO (1) | WO2010085539A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1229045A1 (en) * | 2001-02-01 | 2002-08-07 | Institut Curie | Universal carrier for targeting molecules to Gb3 receptor expressing cells |
| MX2008013363A (es) | 2006-04-20 | 2009-03-26 | Jackson H M Found Military Med | Metodos y composiciones basados en la proteina tipo 1 de la toxina shiga. |
| CA2748873C (en) | 2009-01-23 | 2017-09-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 2 protein |
| US9513287B1 (en) * | 2012-09-28 | 2016-12-06 | The United States Of America, As Represented By The Secretary Of Agriculture | High affinity monoclonal antibodies for detection of shiga toxin 2 |
| US9310368B1 (en) * | 2012-09-28 | 2016-04-12 | The United States Of America, As Represented By The Secretary Of Agriculture | High affinity monoclonal antibodies for detection of Shiga toxin 2 (STX2) |
| CN105051067B (zh) * | 2013-03-12 | 2020-04-17 | 分子模板公司 | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 |
| CN103343164B (zh) * | 2013-06-17 | 2016-05-18 | 武汉轻工大学 | 产志贺毒素大肠杆菌多重pcr检测方法、试剂盒及应用 |
| RU2573924C2 (ru) * | 2013-07-11 | 2016-01-27 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | НЕТОКСИЧНЫЙ РЕКОМБИНАНТНЫЙ ШИГА ТОКСИН 2-ГО ТИПА (Stx2) |
| KR102500408B1 (ko) * | 2014-01-27 | 2023-02-16 | 몰레큘러 템플레이츠, 인코퍼레이션. | 포유류에 적용하기 위한 탈면역된 시가 독소 a 서브유닛 작동체 폴리펩티드 |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| CN113831416A (zh) * | 2014-06-11 | 2021-12-24 | 分子模板公司 | 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子 |
| CN104558167B (zh) * | 2014-12-26 | 2017-12-26 | 江苏省疾病预防控制中心 | 检测i型志贺毒素双抗夹心法酶联免疫试剂盒及其应用 |
| ES2856457T3 (es) | 2015-02-05 | 2021-09-27 | Molecular Templates Inc | Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN107849096B (zh) | 2015-05-30 | 2022-05-24 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN114773439A (zh) | 2016-12-07 | 2022-07-22 | 分子模板公司 | 用于位点特异性缀合的志贺毒素a亚基效应子多肽、志贺毒素效应子支架和细胞靶向分子 |
| MX2019008840A (es) | 2017-01-25 | 2019-09-09 | Molecular Templates Inc | Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+. |
| AU2019257343A1 (en) | 2018-04-17 | 2020-09-10 | Molecular Templates, Inc. | HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds |
| CN115856296B (zh) * | 2022-12-16 | 2023-07-25 | 华北理工大学 | 抗志贺氏菌的单克隆抗体及其检测中的应用 |
| CN120647752B (zh) * | 2025-08-19 | 2025-10-28 | 中国人民解放军军事科学院军事医学研究院 | 一种抗ⅱ型志贺毒素的单克隆抗体及其相关产品和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5164298A (en) | 1988-06-24 | 1992-11-17 | Hsc Research Development Corporation | Verocytotoxin receptor assay |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5552144A (en) * | 1992-01-22 | 1996-09-03 | Microcarb, Inc. | Immunogenic shiga-like toxin II variant mutants |
| US5747272A (en) | 1994-02-14 | 1998-05-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Detection of shiga-like toxins of enterohemoragic Escherichia coli |
| US5968894A (en) | 1994-02-22 | 1999-10-19 | Lingwood; Clifford A. | Verotoxin pharmaceutical compositions and medical treatments therewith |
| EP0929679A2 (en) | 1996-09-10 | 1999-07-21 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof |
| WO1998020903A1 (en) | 1996-11-15 | 1998-05-22 | Trustees Of Tufts College | Humanized neutralizing antibodies against hemolytic uremic syndrome |
| US7910096B2 (en) | 1996-11-15 | 2011-03-22 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic uremic syndrome |
| US20020160005A1 (en) * | 1996-11-15 | 2002-10-31 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic urmec syndrome |
| US20030170248A1 (en) * | 1997-12-23 | 2003-09-11 | Jeffrey R. Stinson | Humanized monoclonal antibodies that protect against shiga toxin induced disease |
| IL139571A0 (en) | 1998-05-20 | 2002-02-10 | Teijin Ltd | A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same |
| ATE504312T1 (de) * | 2003-07-21 | 2011-04-15 | Intervet Int Bv | Hybrid-toxine mit shiga-artigen toxin- untereinheiten, verbunden mit escherichia coli wärmeinstabilen enterotoxin-untereinheiten und vakzine daraus |
| AU2004293502B2 (en) | 2003-11-28 | 2010-12-02 | National Research Council Of Canada | Anticarcinoma antibodies and uses thereof |
| JP2008507253A (ja) | 2004-02-06 | 2008-03-13 | ナイモックス コーポレーション | ヒト化抗体 |
| CA2458084A1 (en) | 2004-03-12 | 2005-09-12 | Dalton Chemical Laboratories Inc. | Novel process for octreotide synthesis |
| WO2006091677A1 (en) * | 2005-02-22 | 2006-08-31 | Jean Gariepy | Yeast strains expressing ribosome-inactivating protein domain and method of using same |
| ES2532985T3 (es) | 2006-02-16 | 2015-04-06 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Proteínas quiméricas de toxoide de Shiga |
| MX2008013363A (es) | 2006-04-20 | 2009-03-26 | Jackson H M Found Military Med | Metodos y composiciones basados en la proteina tipo 1 de la toxina shiga. |
| JP2009538916A (ja) | 2006-05-31 | 2009-11-12 | タリオン ファーマシューティカルズ インコーポレーテッド | 志賀毒素関連病状を治療するための方法、組成物、およびキット |
| US20090258010A1 (en) | 2006-05-31 | 2009-10-15 | Thallion Pharmaceuticals, Inc. | Methods, compositions, and kits for treating shiga toxin associated conditions |
| AU2007339753A1 (en) * | 2006-12-29 | 2008-07-10 | Osprey Pharmaceuticals Usa, Inc. | Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof |
| US20100298238A1 (en) | 2007-10-08 | 2010-11-25 | Rutgers, The State University | Nontoxic shiga-like toxin mutant compositions and methods |
| CN101314616B (zh) * | 2008-05-30 | 2011-05-11 | 中国人民解放军第三军医大学 | 肠出血性大肠杆菌o157:h7志贺毒素ⅱb表位肽及其应用 |
| US20110165680A1 (en) * | 2008-09-12 | 2011-07-07 | Scarab Genomics, Llc | Clean genome bactofection |
| CA2748873C (en) | 2009-01-23 | 2017-09-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 2 protein |
-
2010
- 2010-01-21 CA CA2748873A patent/CA2748873C/en active Active
- 2010-01-21 CN CN2010800052595A patent/CN102292098A/zh active Pending
- 2010-01-21 AU AU2010206800A patent/AU2010206800B2/en active Active
- 2010-01-21 EP EP10733840.2A patent/EP2381954B8/en active Active
- 2010-01-21 PE PE2011001368A patent/PE20120425A1/es not_active Application Discontinuation
- 2010-01-21 RU RU2011126896/10A patent/RU2011126896A/ru not_active Application Discontinuation
- 2010-01-21 US US13/142,556 patent/US8969529B2/en active Active
- 2010-01-21 ES ES10733840.2T patent/ES2614803T3/es active Active
- 2010-01-21 JP JP2011548095A patent/JP5773886B2/ja active Active
- 2010-01-21 MX MX2011007866A patent/MX2011007866A/es unknown
- 2010-01-21 NZ NZ593926A patent/NZ593926A/xx not_active IP Right Cessation
- 2010-01-21 KR KR1020117019455A patent/KR101832499B1/ko not_active Expired - Fee Related
- 2010-01-21 WO PCT/US2010/021610 patent/WO2010085539A1/en not_active Ceased
- 2010-01-21 BR BRPI1007230-6A patent/BRPI1007230B1/pt not_active IP Right Cessation
- 2010-01-22 AR ARP100100141A patent/AR075047A1/es not_active Application Discontinuation
-
2011
- 2011-07-21 CL CL2011001769A patent/CL2011001769A1/es unknown
-
2015
- 2015-02-23 US US14/628,667 patent/US9801931B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5773886B2 (ja) | 2015-09-02 |
| BRPI1007230B1 (pt) | 2019-11-12 |
| EP2381954A1 (en) | 2011-11-02 |
| US8969529B2 (en) | 2015-03-03 |
| PE20120425A1 (es) | 2012-05-03 |
| EP2381954B1 (en) | 2016-11-02 |
| RU2011126896A (ru) | 2013-02-27 |
| EP2381954B8 (en) | 2017-01-25 |
| CA2748873A1 (en) | 2010-07-29 |
| AR075047A1 (es) | 2011-03-02 |
| US20160243210A1 (en) | 2016-08-25 |
| KR20110119725A (ko) | 2011-11-02 |
| WO2010085539A1 (en) | 2010-07-29 |
| KR101832499B1 (ko) | 2018-02-26 |
| CN102292098A (zh) | 2011-12-21 |
| CA2748873C (en) | 2017-09-12 |
| US20110318357A1 (en) | 2011-12-29 |
| ES2614803T3 (es) | 2017-06-02 |
| MX2011007866A (es) | 2011-10-06 |
| BRPI1007230A2 (pt) | 2016-02-16 |
| NZ593926A (en) | 2013-03-28 |
| US9801931B2 (en) | 2017-10-31 |
| EP2381954A4 (en) | 2012-08-01 |
| AU2010206800A1 (en) | 2011-07-28 |
| AU2010206800B2 (en) | 2016-06-30 |
| JP2012515551A (ja) | 2012-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011001769A1 (es) | Composición para estimular una respuesta inmune contra la toxina shiga stx2 que comprende polipéptidos que comprenden al menos dos de las tres regiones que definen un epitopo conformacional exclusivo de stx2, los cuales se insertan dentro de una proteína andamio no stx2; dicho polipéptido; ácido nucleico; y método de producción de anticuerpos. | |
| ECSP13012877A (es) | FORMAS SÓLIDAS SDE 3- (5-AMINO-2-metil -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, Y SUS COMPOSICIONES FARMACÉUTICAS Y USOS | |
| BR112018004965A2 (pt) | domínios de superfamìlia de imunoglobulina variante ajustàvel | |
| BR112013021134A8 (pt) | Anticorpo isolado que se liga especificamente a ptk7 humano, seu uso, composição farmacêutica que o compreende, e ácido nucleico | |
| CL2011002943A1 (es) | Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica. | |
| CO2018012513A2 (es) | Anticuerpos | |
| AR089529A1 (es) | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17 | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| CY1115091T1 (el) | Διειδικες πρωτεϊνες προσδεσης αντιγονων | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| UY32501A (es) | Anticuerpo antagonista específico para el heterodímero alfa4-beta7 | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| PE20190229A1 (es) | Anticuerpos anti-fcrn | |
| MX2016002166A (es) | Anticuerpos. | |
| AR088920A1 (es) | Purificacion de anticuerpos anti-c-met | |
| MX2019002979A (es) | Formulaciones de anticuerpos. | |
| CO6680687A2 (es) | Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas | |
| AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
| AR088514A1 (es) | Inmunoligantes biespecificos dirigidos contra tnf | |
| DK2044076T3 (da) | Fremgangsmåde til fremstilling af asenapin og intermediatprodukter, som anvendes i fremgangsmåden | |
| BR112015023797A2 (pt) | proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17 | |
| BR112016015105A2 (pt) | Conjugados var2csa-droga | |
| BR112013003522A2 (pt) | "polipeptídeos relaxina modificados compreendeendo um aminoácido não codificado naturalmente, uso, método de preparação, bem como ácido nucleico codificando os mesmos" | |
| BR112017016897A2 (pt) | cepas fúngicas e métodos de uso | |
| BR112014029274A2 (pt) | anticorpo isolado, composição farmacêutica, uso do anticorpo, método para tratar infecção rábica, kit para tratar infecção rábica, kit para detectar vírus rábico, ácido nucleico isolado, e, célula hospedeira. |